Can I provide my own scaffold sequence for library construction?

Absolutely. We offer Scaffold Library Construction services for client-proprietary frameworks, ensuring strict confidentiality and intellectual property protection.

How do you ensure the binders are non-immunogenic?

We utilize human-derived scaffolds as the starting point and employ in silico T-cell epitope prediction tools to minimize immunogenic risk during the design phase.

Which display technology is best for my project?

This depends on the scaffold. Phage display is excellent for high-throughput, while yeast display allows for better quality control via FACS. Our experts will recommend the most suitable platform during the initial consultation.

How does the size of a scaffold impact its "druggability"?

Smaller scaffolds (5-15 kDa) offer significantly better tissue penetration than 150 kDa antibodies. This makes them ideal for treating dense solid tumors. Furthermore, their simple structure allows for high-yield production in E. coli, reducing cost.

What is the risk of immunogenicity with non-human scaffolds?

We mitigate this during the Scaffold Sequence Design phase. We prioritize scaffolds with high structural homology to human proteins and use in silico tools to remove potential MHC-II binding peptides, ensuring a "low-immunogenicity" profile.

Can you perform screening against GPCRs or Ion Channels?

Yes. For complex membrane proteins, we utilize cell-based Scaffold Library Screening or liposome-embedded antigens to ensure the scaffold recognizes the protein in its native lipid environment.

Engineered Protein Scaffold Discovery Service: Pioneering the Next Generation of Biotherapeutics

Background Design Construction Screening Workflow Advantage FAQ Online Inquiry

In the rapidly evolving landscape of biotechnology, the quest for highly stable, small, and efficacious binding molecules has led to the emergence of Engineered Protein Scaffolds. While monoclonal antibodies (mAbs) have dominated the market for decades, protein scaffolds offer unique advantages in terms of tissue penetration, stability, and manufacturing costs. At Creative Biolabs, with over two decades of industry-leading experience, we provide a comprehensive, end-to-end Engineered Protein Scaffold Discovery Service tailored to meet the most rigorous demands of global researchers.

Discuss Your Project Today

Introduction to Engineered Protein Scaffolds

Protein scaffolds are non-antibody proteins that can be engineered to bind specifically to a target molecule with high affinity. Unlike the complex Y-shaped structure of antibodies, these scaffolds are typically small, single-domain proteins with high thermal and chemical stability.

Why Choose Protein Scaffolds over Traditional Antibodies?

The limitations of traditional antibodies—such as their large size (~150 kDa), complex disulfide bond requirements, and potential for immunogenicity—have paved the way for "antibody mimetics." Engineered scaffolds typically range from 5 to 20 kDa, allowing for:

Superior Tissue Penetration: Ideal for solid tumor targeting.
High Stability: Resistant to extreme pH and temperature.
Ease of Production: Can be efficiently expressed in microbial systems like E. coli.
Versatile Formats: Easily fused into multispecific or multivalent constructs.

Cutting-Edge Scaffold Sequence Design

The foundation of a successful discovery program lies in Scaffold Sequence Design. Creative Biolabs utilizes a "Structure-Guided and AI-Driven" approach.

AI and Computational Modeling

We leverage the latest advancements in structural biology, including:

Computational Protein Structure Prediction: For precise 3D structure prediction of de novo scaffolds.
Molecular Dynamics (MD) Simulations: To assess the conformational stability of designed sequences under physiological conditions.
Machine Learning for Library Design: Using Deep Learning algorithms to predict "developability" scores, ensuring that the designed sequences are not only high-affinity binders but also soluble and non-aggregating.

Rational Design Strategies

Loop Grafting: Transferring known binding motifs onto stable frameworks.
Surface Engineering: Modifying the scaffold surface to improve pharmacokinetics and reduce immunogenicity.
Stability Enhancement: Introducing non-canonical amino acids or salt bridges to further fortify the scaffold.

High-Throughput Scaffold Library Construction: Precision at the Molecular Level

The success of Engineered Protein Scaffold Discovery is fundamentally tied to the quality of the initial library. At Creative Biolabs, we believe that "diversity is not just about numbers; it is about the right numbers." A library with 10¹² poorly designed clones is less valuable than one with 10⁹ strategically designed variants. Our Scaffold Library Construction platform is built on this philosophy of "Precision Diversity."

Strategic Design Philosophies

We employ three primary strategies for library generation, depending on the structural constraints of the Scaffold Protein:

Site-Saturation Mutagenesis: Every amino acid in a targeted loop or binding interface is replaced by all 20 standard amino acids. This is ideal for fine-tuning existing binders.
Combinatorial Randomization: Using degenerate codons to introduce vast diversity across multiple loops simultaneously.
Soft Randomization: Keeping the wild-type residue at a higher frequency while allowing for low-level mutations, preserving the structural integrity of the scaffold.

Trimer Codon Technology: The Gold Standard

Traditional degenerate codons often introduce unwanted stop codons or redundant amino acids (e.g., three different codons for Leucine). Creative Biolabs utilizes Trimer Codon Synthesis to overcome these limitations.

No Stop Codons: Eliminates truncated proteins that waste library space.
Custom Amino Acid Ratios: We can exclude "troublesome" residues like Cysteine (to avoid unwanted disulfide bonds) or Proline (to avoid structural disruption) while enriching for residues like Tyrosine and Serine, which are statistically favored in binding interfaces.
Maximum Functional Diversity: Ensures that every clone in the library has the potential to be a viable, foldable binder.

Advanced Scaffold Library Screening Platforms: Speed and Stringency

Once the library is constructed, the challenge shifts to Scaffold Library Screening. Creative Biolabs offers the industry's most versatile selection toolkit, ensuring that we can find the "needle in the haystack" regardless of target complexity.

Phage Display: The Versatile Workhorse

Our Phage Display system is optimized for Scaffold Library Screening against a variety of targets, including recombinant proteins, haptens, and even whole cells.

Bio-panning Sophistication: We utilize competitive elution and negative selection (depletion) against non-target proteins to ensure exceptional specificity.
Adaptability: Suitable for scaffolds like Monobodies.

Fig. 1 Helix bundle–DARPin–apoferritin–helix bundle scaffold. (OA Literature) Fig. 1 Design of the helix bundle–DARPin–apoferritin–helix bundle scaffold.¹

Yeast Surface Display: Real-time Characterization

For projects requiring eukaryotic post-translational considerations or precise affinity discrimination, yeast display is the platform of choice.

FACS-Aided Selection: We use Fluorescence-Activated Cell Sorting to quantitatively "gate" for clones with the highest affinity and best expression levels simultaneously.
Fine-Tuning: Ideal for Scaffold Sequence Design optimization, as it allows us to visualize the binding kinetics directly on the cell surface.

mRNA and Ribosome Display: Breaking the Diversity Barrier

For de novo Engineered Protein Scaffold Discovery, we often utilize cell-free display systems.

Unprecedented Library Size: Since we are not limited by bacterial transformation efficiency, we can screen libraries of up to 10¹⁵ members.
In Vitro Evolution: Allows rapid cycles of mutation and selection without the need for cloning, accelerating the discovery of ultra-high affinity binders.

NGS-Integrated Selection: The "Big Data" Advantage

We don't just pick colonies; we sequence the entire selection pool. By applying Next-Generation Sequencing (NGS) to multiple rounds of screening, we can:

Identify "hidden gems" (clones that are highly potent but might grow slowly in culture).
Track the enrichment trajectory of specific sequence motifs.
Predict the best candidates using bioinformatic algorithms before manual validation.

The Creative Biolabs Discovery Workflow: From Sequence to Lead

Our integrated workflow is designed to minimize risk and maximize the "developability" of your lead Scaffold Protein.

01Phase I: In Silico Design & Target Prep

Target Validation: We produce and quality-control the target antigen in-house to ensure it is in its native, bioactive conformation.
Scaffold Sequence Design: Utilizing AI-driven structural modeling to identify the optimal hypervariable regions for randomization.

02Phase II: Library Generation & QC

Synthesis: High-fidelity DNA synthesis of the designed library.
Validation: Every library undergoes validation to confirm its diversity and sequence distribution before entering the screening phase.

03Phase III: Multi-Platform Screening

Iterative Panning: 3-5 rounds of selection with increasing stringency (reduced target concentration, increased washing steps).
Specific Elution: Utilizing ligand-specific elution to capture binders targeting functional epitopes.

04Phase IV: Characterization & Optimization

High-Throughput Expression: Hit clones are expressed for primary ELISA screening.
Biophysical Profiling: affinity, stability, and solubility.

Why We Lead the Industry

Unrivaled Expertise: With 20+ years of focus on protein engineering, we have successfully delivered over 500 scaffold discovery projects targeting oncology, immunology, and infectious diseases.
Integrated AI-Platform: We are one of the few providers that seamlessly integrate wet-lab screening with dry-lab computational design, significantly shortening the discovery timeline.
Global Compliance: All our processes are conducted in state-of-the-art facilities, adhering to the highest international standards of research and development.

The future of biotherapeutics lies beyond the antibody. Engineered Protein Scaffolds represent a paradigm shift, offering flexibility and performance that antibodies cannot match. Partner with Creative Biolabs to leverage our world-class expertise in Scaffold Sequence Design, Library Construction, and High-Throughput Screening. Together, we can transform your therapeutic vision into reality.

Contact us today to discuss your next Engineered Protein Scaffold Discovery project.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Can I provide my own scaffold sequence for library construction?
Absolutely. We offer Scaffold Library Construction services for client-proprietary frameworks, ensuring strict confidentiality and intellectual property protection.
How do you ensure the binders are non-immunogenic?
We utilize human-derived scaffolds as the starting point and employ in silico T-cell epitope prediction tools to minimize immunogenic risk during the design phase.
Which display technology is best for my project?
This depends on the scaffold. Phage display is excellent for high-throughput, while yeast display allows for better quality control via FACS. Our experts will recommend the most suitable platform during the initial consultation.
How does the size of a scaffold impact its "druggability"?
Smaller scaffolds (5-15 kDa) offer significantly better tissue penetration than 150 kDa antibodies. This makes them ideal for treating dense solid tumors. Furthermore, their simple structure allows for high-yield production in E. coli, reducing cost.
What is the risk of immunogenicity with non-human scaffolds?
We mitigate this during the Scaffold Sequence Design phase. We prioritize scaffolds with high structural homology to human proteins and use in silico tools to remove potential MHC-II binding peptides, ensuring a "low-immunogenicity" profile.
Can you perform screening against GPCRs or Ion Channels?
Yes. For complex membrane proteins, we utilize cell-based Scaffold Library Screening or liposome-embedded antigens to ensure the scaffold recognizes the protein in its native lipid environment.

References

Lu, Xin, et al. "A large, general and modular DARPin–apoferritin scaffold enables the visualization of small proteins by cryo-EM." IUCrJ 12.3 (2025). Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1107/S2052252525003021

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.